Immunological correlates of protection for the RTS,S candidate malaria vaccine (Q39032713)

8 September 2017

Immunological correlates of protection for the RTS,S candidate malaria vaccine (English)

1 reference

8 September 2017

0 references

1 reference

1

Brian Greenwood

1 reference

PubMed ID

21237716

8 September 2017

language of work or name

1 reference

13 January 2011

1 reference

Lancet Infectious Diseases

8 September 2017

1 reference

8 September 2017

11

1 reference

8 September 2017

2

1 reference

8 September 2017

75-76

1 reference

Efficacy of RTS,S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5-17 months in Kenya and Tanzania: a randomised controlled trial

8 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970001-9

7 January 2021

Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970001-9

7 January 2021

The RTS,S malaria vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970001-9

7 January 2021

Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970001-9

7 January 2021

Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970001-9

7 January 2021

Phase 2a trial of 0, 1, and 3 month and 0, 7, and 28 day immunization schedules of malaria vaccine RTS,S/AS02 in malaria-naïve adults at the Walter Reed Army Institute of Research

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970001-9

7 January 2021

Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970001-9

7 January 2021

Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled phase I/IIb trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970001-9

7 January 2021

Safety and immunogenicity of RTS,S/AS02D malaria vaccine in infants

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970001-9

7 January 2021

Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970001-9

7 January 2021

Protective immunity induced with malaria vaccine, RTS,S, is linked to Plasmodium falciparum circumsporozoite protein-specific CD4+ and CD8+ T cells producing IFN-gamma.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970001-9

7 January 2021

Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970001-9

7 January 2021

Plasmodium falciparum-specific cellular immune responses after immunization with the RTS,S/AS02D candidate malaria vaccine in infants living in an area of high endemicity in Mozambique

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970001-9

7 January 2021

10.1016/S1473-3099(11)70001-9

Identifiers

DOI

1 reference

8 September 2017

1 reference

PubMed ID

21237716